Buch

---

Übersicht

---

Verlag	:	Springer International Publishing
Buchreihe	:	Resistance to Targeted Anti-Cancer Therapeutics (Bd. 16)
Sprache	:	Englisch
Erschienen	:	23. 06. 2018
Seiten	:	184
Einband	:	Kartoniert
Höhe	:	235 mm
Breite	:	155 mm
Gewicht	:	314 g
ISBN	:	9783319888910
Sprache	:	Englisch

---

Autorinformation

---

Dr. Prosperi received her BA in Microbiology from Miami University (OH), and went on to get a PhD in Integrated Biomedical Science (focus: Cancer Biology) at The Ohio State University. She joined a laboratory focused on breast cancer research, and started volunteering at The James Cancer Hospital and with The Komen Foundation. She then completed postdoctoral studies at the University of Chicago, where she started to focus on the APC tumor suppressor and developing targeted therapies for breast cancer. In 2012, she was recruited to Indiana University School of Medicine – South Bend with an adjunct faculty position at the University of Notre Dame. Through these affiliations, she has been a member of both the Simon Cancer Center and the Harper Cancer Research Institute since 2012. Her laboratory is focused on the understanding of resistance to chemotherapy in breast cancer patients, specifically how the APC tumor suppressor impacts this process.

Inhaltsverzeichnis

---

Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target?.- Resistance to HER2-targeted therapy.- Endocrine Resistance and Breast Cancer Stem Cells – The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes.- EGFR Resistance.- Targeting FGFR for the treatment of breast cancer.- Targeted Therapies in Breast Cancer.- Future paradigm of breast cancer resistance and treatment.

Deine Buchhandlung

---